Literature DB >> 15992653

The changing face of cardiovascular risk.

Scott M Grundy.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15992653     DOI： 10.1016/j.jacc.2005.05.007

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  9 in total

1.  Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes.

Authors:  Emily G Kurtz; Paul M Ridker; Lynda M Rose; Nancy R Cook; Brendan M Everett; Julie E Buring; Kathryn M Rexrode
Journal:  Menopause       Date:  2011-01       Impact factor: 2.953

Review 2.  Role of noninvasive imaging in asymptomatic high-risk patients.

Authors:  Leslee J Shaw; Allen Taylor; Paolo Raggi; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

3.  Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study.

Authors:  David M Leistner; Jens Klotsche; Lars Pieper; Sylvia Palm; Günter K Stalla; Hendrik Lehnert; Sigmund Silber; Winfried März; Hans-Ulrich Wittchen; Andreas M Zeiher
Journal:  Clin Res Cardiol       Date:  2013-01-04       Impact factor: 5.460

Review 4.  Role of computed tomography in risk assessment for coronary heart disease.

Authors:  Tarun K Mittal; Mahmoud Barbir; Michael Rubens
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

Review 5.  Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.

Authors:  Thomas Dayspring; Gregory Pokrywka
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

6.  Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.

Authors:  Marc De Hert; Aurélia Mittoux; Yuan He; Joseph Peuskens
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-09-05       Impact factor: 5.270

7.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 8.  Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Authors:  Marcello Arca; Achille Gaspardone
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Twelve-month outcomes in overweight/obese users with mental disorders following a multi-element treatment including diet, physical activity, and positive thinking: The real-world "An Apple a Day" controlled trial.

Authors:  Laura Giusti; Valeria Bianchini; Annalisa Aggio; Silvia Mammarella; Anna Salza; Stefano Necozione; Alessia Alunno; Claudio Ferri; Massimo Casacchia; Rita Roncone
Journal:  Front Psychiatry       Date:  2022-08-23       Impact factor: 5.435
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.